Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells

Zoledronic acid, a potent nitrogen-containing bisphosphonate (NBP), has been extensively used to limit bone turnover in a various diseases including tumors. Recent clinical studies have demonstrated direct anti-cancer effects of zoledronic acid, in addition to its clinical benefits for skeletal-related events. Here we investigated the effects of 4 clinically available NBPs on human tumor cell proliferation. Our data demonstrate a potent anti-proliferative effect of zoledronic acid against glioblastoma (GBM) cell lines, breast cancer cells and GBM patient-derived lines. Zoledronic acid also effectively inhibited GBM tumor growth in xenograft mouse models. Zoledronic acid strongly stimulated autophagy but not apoptotic signals in all tested cells. Only one intermediate product of cholesterols synthesis pathway, geranylgeranyl diphosphate (GGPP) rescued cells from the cytotoxic effects of zoledronic acid. To further investigate the effect of GGPP, we knocked down RABGGTA, which encodes a subunit of the Rabgeranylgeranyltransferase protein. This knockdown induced an effect similar to zoledronic acid in cancer cell lines. These data are promising and suggested a potential for zoledronic acid as an anti-cancer agent, through its ablation of the function of Rab proteins.

[1]  Y. Tu,et al.  Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity , 2015 .

[2]  D. Kamp,et al.  miR-5100 promotes tumor growth in lung cancer by targeting Rab6. , 2015, Cancer letters.

[3]  T. Ohm,et al.  Geranylgeranyl pyrophosphate is crucial for neuronal survival but has no special role in Purkinje cell degeneration in Niemann Pick type C1 disease , 2015, Journal of neurochemistry.

[4]  S. Pastorino,et al.  In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells , 2014, British Journal of Cancer.

[5]  Panagiotis Karras,et al.  RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. , 2014, Cancer cell.

[6]  Q. Ni,et al.  High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival , 2014, Medical Oncology.

[7]  Taher Abbasi,et al.  Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs , 2014, Journal of Translational Medicine.

[8]  J. Carles,et al.  Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study , 2013, British Journal of Cancer.

[9]  Alireza Khoshnevisan,et al.  A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care , 2013, Oncotarget.

[10]  R. Goody,et al.  Development of selective, potent RabGGTase inhibitors. , 2012, Journal of medicinal chemistry.

[11]  Hiroshi Kobayashi,et al.  Zoledronic Acid Produces Antitumor Effects on Mesothelioma Through Apoptosis and S-Phase Arrest in p53-Independent and Ras prenylation-Independent Manners , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  R. Goody,et al.  Psoromic acid is a selective and covalent Rab-prenylation inhibitor targeting autoinhibited RabGGTase. , 2012, Journal of the American Chemical Society.

[13]  J. Cui,et al.  Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma. , 2012, World journal of gastroenterology.

[14]  E. Oldfield,et al.  Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity , 2012, Proceedings of the National Academy of Sciences.

[15]  M. Pilon,et al.  The mevalonate pathway in C. Elegans , 2011, Lipids in Health and Disease.

[16]  S. Sebti,et al.  Targeting protein prenylation for cancer therapy , 2011, Nature Reviews Cancer.

[17]  W. Gregory,et al.  Breast-cancer adjuvant therapy with zoledronic acid. , 2011, The New England journal of medicine.

[18]  R. Coleman,et al.  Anticancer evidence for zoledronic acid across the cancer continuum. , 2011, Critical reviews in oncology/hematology.

[19]  M. Scheper,et al.  Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers , 2011, Journal of carcinogenesis.

[20]  C. Agrati,et al.  Zoledronic Acid Enhances Vδ2 T-Lymphocyte Antitumor Response to Human Glioma Cell Lines , 2011, International journal of immunopathology and pharmacology.

[21]  A. Bhangu-Uhlmann.  The mevalonate pathway , 2011 .

[22]  I. Holen,et al.  Anti-tumour activity of bisphosphonates in preclinical models of breast cancer , 2010, Breast Cancer Research.

[23]  P. Boutros,et al.  Dysregulation of the mevalonate pathway promotes transformation , 2010, Proceedings of the National Academy of Sciences.

[24]  K. Nackaerts,et al.  Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  Ting-Kai Chang,et al.  Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. , 2009, Journal of the American Chemical Society.

[26]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[27]  Z. Shao,et al.  Enhanced Expression of Rab27A Gene by Breast Cancer Cells Promoting Invasiveness and the Metastasis Potential by Secretion of Insulin-Like Growth Factor-II , 2008, Molecular Cancer Research.

[28]  M. Caraglia,et al.  Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.

[29]  E. Oldfield,et al.  Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases , 2007, Proceedings of the National Academy of Sciences.

[30]  G. A. van der Marel,et al.  Inhibitors of protein: geranylgeranyl transferases. , 2006, Current medicinal chemistry.

[31]  S. Knapp,et al.  The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Thoulouzan,et al.  Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells , 2006, BMC Cancer.

[33]  Brad E. Pfeiffer,et al.  Brain cholesterol turnover required for geranylgeraniol production and learning in mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Casey,et al.  Conversion of protein farnesyltransferase to a geranylgeranyltransferase. , 2006, Biochemistry.

[35]  J. Hohneker,et al.  Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. , 2003, Seminars in oncology.

[36]  M. Glatt,et al.  Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). , 2002, Journal of medicinal chemistry.

[37]  H. Goodson,et al.  Late endosome motility depends on lipids via the small GTPase Rab7 , 2002, The EMBO journal.

[38]  B. Roe,et al.  The gene for the muted (mu) mouse, a model for Hermansky-Pudlak syndrome, defines a novel protein which regulates vesicle trafficking. , 2002, Human molecular genetics.

[39]  K. Colston,et al.  The potential role of bisphosphonates in prostate cancer , 2002, Prostate Cancer and Prostatic Diseases.

[40]  Harald Stenmark,et al.  The Rab GTPase family , 2001, Genome Biology.

[41]  F. Singer,et al.  Bisphosphonate treatment inhibits the growth of prostate cancer cells. , 2001, Cancer research.

[42]  L. Collinson,et al.  Rab27a Regulates the Peripheral Distribution of Melanosomes in Melanocytes , 2001, Journal of Cell Biology.

[43]  C. Poulter,et al.  Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. , 2001, The Journal of pharmacology and experimental therapeutics.

[44]  S. Kingsmore,et al.  Rab geranylgeranyl transferase alpha mutation in the gunmetal mouse reduces Rab prenylation and platelet synthesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Kasiske,et al.  Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis. , 1999, Kidney international. Supplement.

[46]  B. Goud,et al.  Interaction of a Golgi-associated kinesin-like protein with Rab6. , 1998, Science.

[47]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[48]  Y. Masuda,et al.  Geranylgeraniol is a potent inducer of apoptosis in tumor cells. , 1995, Journal of biochemistry.

[49]  K. Jaeggi,et al.  Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  P. Casey,et al.  Protein farnesyltransferase and geranylgeranyltransferase share a common α subunit , 1991, Cell.

[51]  P. Casey,et al.  Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. , 1991, Cell.